ALEC NASDAQ
Alector, Inc.
1W: -6.2%
1M: -6.2%
3M: +20.4%
YTD: +19.6%
1Y: +24.5%
3Y: -64.8%
5Y: -92.2%
$2.10
+0.27 (+14.75%)
After Hours: $1.99 (-0.11, -5.00%)
Weekly Expected Move ±11.0%
$1
$2
$2
$2
$2
Credit Risk of going bust: higher than 66% of companies Debt: 13.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.03 (down 98%), Alector, Inc. would be worth roughly what it owes.
Total debt $32.8M against a stock market value of $204.3M.
Distance to default 3.71 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $9.8M (short-term plus half of long-term), stock volatility 79.7%; Altman Z'' -15.59. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.03 (down 98%), Alector, Inc. would be worth roughly what it owes.
Total debt $32.8M against a stock market value of $204.3M.
Distance to default 3.71 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $9.8M (short-term plus half of long-term), stock volatility 79.7%; Altman Z'' -15.59. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$204.3M
52W Range1.09-2.76
Volume2,658,132
Avg Volume2,498,548
Beta0.62
Dividend—
Analyst Ratings
Company Info
CEOArnon Rosenthal
Employees103
SectorHealthcare
IndustryBiotechnology
IPO Date2019-02-07
Websitealector.com
131 Oyster Point Boulevard
South San Francisco, CA 94080
US
South San Francisco, CA 94080
US
415 231 5660
About Alector, Inc.
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
Latest News
Alector rises after pricing $75M equity offering
Alector Sees Unusually High Options Volume (NASDAQ:ALEC)
Alector surges on licensing agreement with Genentech
Biotech Brainiacs and Breakthroughs
Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Rosenthal Arnon | A-Award | 217,500 | — | 2026-10-14 |
| Rosenthal Arnon | A-Award | 978,750 | $1.88 | 2026-10-14 |
| Wong-Sarad Grace | A-Award | 55,555 | — | 2026-10-14 |
| Wong-Sarad Grace | A-Award | 83,435 | $1.88 | 2026-10-14 |
| Berkley Neil Lindsay | A-Award | 44,567 | — | 2026-10-14 |